In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients

Rolston, Kenneth V. I.; Frisbee-Hume, Susan; LeBlanc, Barbara; Streeter, Harriet; Ho, Dah Hsi

doi:10.1016/s0732-8893(03)00115-9

Cited by 35 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The potent activity of moxifloxacin against Aerococcus spp. is concordant with data previously reported (8). Finally, active efflux did not seem to play a major role in fluoroquinolone resistance in aerococci, since the MICs of ciprofloxacin were similar in the absence or presence of reserpin (Table 1).…”

supporting

confidence: 92%

First Molecular Characterization of Fluoroquinolone Resistance in Aerococcus spp

Cattoir

Kobal

Legrand

2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

supporting

confidence: 92%

First Molecular Characterization of Fluoroquinolone Resistance in Aerococcus spp

Cattoir

Kobal

Legrand

2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…There were 21 women and 19 men with a median age of 44 years (range, 20-71 years). The median MASCC score was 24 (range, [16][17][18][19][20][21][22][23][24][25][26]. 7 Four patients had MASCC scores Ͻ21.…”

Section: Patient Characteristicsmentioning

confidence: 99%

Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia

Rolston

Manzullo

Elting

et al. 2006

Cancer

View full text Add to dashboard Cite

Nucleation of isotactic polypropylene (iPP) crystallization by gold (Au) nanoparticles was studied. Regardless of their size, 4.3, 8.8, 28.3, and 84.5 nm, all particles were able to nucleate spherulites when deposited on the iPP surface. However, when added and melt‐mixed with iPP, only the smallest particles affected significantly the iPP bulk crystallization. Au nanoparticles larger than 4.3 nm, at the concentration of 0.001 wt %, did not influence the crystallization of iPP. Contrary to this, 0.001 and 0.005 wt % of Au nanoparticles having the size of 4.3 nm increased crystallization temperature of the iPP by 7–8 °C and decreased markedly the sizes of polycrystalline aggregates. Aggregation of Au nanoparticles in the polymer matrix was evidenced by electron microscopy and contributed to their decreased effectiveness in the nucleation of iPP crystallization. © 2010 Wiley Periodicals, Inc. J Polym Sci Part B: Polym Phys 48: 469–478, 2010

show abstract

“…Levofloxacin, a newer member of the quinolone class, also has activity against P. aeruginosa, albeit usually to a lesser degree, as evidenced by higher MICs than those of ciprofloxacin (5,16,22,24,27). With the widespread use of quinolones both in the hospital and in the community setting, resistance to ciprofloxacin and levofloxacin among P. aeruginosa isolates has emerged and continues to rapidly escalate (3, 4).…”

mentioning

confidence: 99%

Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa

Kaye

Kanafani

Dodds

et al. 2006

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Due to the greater in vitro activity of ciprofloxacin than that of levofloxacin against Pseudomonas aeruginosa, the likelihood of isolating a clinical strain of quinolone-resistant (QR) P. aeruginosa might be greater after exposure to levofloxacin than ciprofloxacin. We examined the risk of isolating QR P. aeruginosa in association with prior levofloxacin or ciprofloxacin exposure. A case-case-control study was conducted. Two groups of cases, one with nosocomial QR P. aeruginosa infections and one with nosocomial quinolone-susceptible (QS) P. aeruginosa infections, were compared to a control group of hospitalized patients without P. aeruginosa infections. Bivariable and multivariable analyses were used to determine risk factors for isolation of QR P. aeruginosa and QS P. aeruginosa. One hundred seventeen QR P. aeruginosa and 255 QS P. aeruginosa cases were identified, and 739 controls were selected. Exposures to ciprofloxacin were similar among all three groups (8% for controls, 9.4% for QR P. aeruginosa cases, and 7.5% for QS P. aeruginosa cases; P > 0.6). Levofloxacin use was more frequent in the QR P. aeruginosa cases than in the controls (35.9% and 22.1%, respectively; odds ratio [OR] ‫؍‬ 2.0; 95% confidence interval [CI] ‫؍‬ 1.3 to 3.0) and less frequent in QS P. aeruginosa cases (14.1% of QS P. aeruginosa cases; OR ‫؍‬ 0.6; 95% CI ‫؍‬ 0.4 to 0.9). In multivariable analysis, levofloxacin, but not ciprofloxacin, was a significant risk factor for isolation of QR P. aeruginosa (OR for levofloxacin ‫؍‬ 1.7 [95% CI ‫؍‬ 1.0 to 2.9]; OR for ciprofloxacin ‫؍‬ 1.2 [95% CI ‫؍‬ 0.6 to 2.5]). Levofloxacin was associated with a reduced risk of isolation of QS P. aeruginosa (OR ‫؍‬ 0.6; 95% CI ‫؍‬ 0.4 to 0.9), whereas ciprofloxacin had no significant effect (OR ‫؍‬ 1.0; 95% CI ‫؍‬ 0.6 to 1.8). In conclusion, the use of levofloxacin, but not ciprofloxacin, was associated with isolation of QR P. aeruginosa.Pseudomonas aeruginosa continues to be a major pathogen in nosocomial infections, ranking fifth among all organisms isolated and first among organisms causing infections in medical intensive care units (ICUs) in the United States (17, 23). P. aeruginosa causes a wide range of infections, some life threatening, such as bacteremia and pneumonia. In recent years, this organism has become increasingly resistant to various antimicrobial agents (6, 7).Among the fluoroquinolones, ciprofloxacin has been most commonly used for the treatment of infections caused by P. aeruginosa. Levofloxacin, a newer member of the quinolone class, also has activity against P. aeruginosa, albeit usually to a lesser degree, as evidenced by higher MICs than those of ciprofloxacin (5,16,22,24,27). With the widespread use of quinolones both in the hospital and in the community setting, resistance to ciprofloxacin and levofloxacin among P. aeruginosa isolates has emerged and continues to rapidly escalate (3, 4). However, data quantifying the impact of fluoroquinolone use on the risk of isolation of quinolone-resistant (QR) P. aeruginosa are limited and...

show abstract

In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients

Cited by 35 publications

References 45 publications

First Molecular Characterization of Fluoroquinolone Resistance in Aerococcus spp

First Molecular Characterization of Fluoroquinolone Resistance in Aerococcus spp

Once daily, oral, outpatient quinolone monotherapy for low‐risk cancer patients with fever and neutropenia

Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa

Contact Info

Product

Resources

About